Cemiplimab

Cemiplimab

Cemiplimab is a programmed death receptor-1 (PD-1)–blocking antibody or immune checkpoint inhibitor. 

The drug has several indications, including the treatment of patients with:

  • Metastatic basal cell carcinoma
  • Locally advanced basal cell carcinoma
  • Metastatic cutaneous squamous cell carcinoma
  • Locally advanced cutaneous squamous cell carcinoma
  • Non-small cell lung cancer

Provider Resources